Interacties en dubbelmedicatie bij poliklinische patiënten met kanker

Translated title of the contribution: Drug interactions and duplicate prescriptions in outpatients receiving cancer treatment

Roelof W.F. Van Leeuwen, Eleonora L. Swart, Frits A. Boom, Martin G. Schuirenmaker, Jacqueline S. Hugtenburg

Research output: Contribution to journalArticleAcademicpeer-review


Objective: The pharmacotherapeutic treatment of patients with cancer is generally associated with multiple side-effects. Drug interactions can reinforce or intensify side-effects. We assessed the prevalence of drug interactions among ambulatory cancer patients being treated with cytotoxic drugs using a novel advanced screening method. Design and methods: The patients were asked to complete a questionnaire and an interview to obtain demographic and medication data. Drug interactions were identified by using electronic (Drug Interaction Facts software, version 4.0) and manual (e.g. PubMed) screening methods. Results: In this study 278 patients were enrolled and 348 potential drug interactions were identified. Of all patients 161 (58%; 95% confidence interval 52-64%) experienced at least one interaction. Of all drug interactions 34% was classified as major and 60% as moderate. In 40% of all drug interactions an anti-cancer agent and in 60% a supportive agent was involved. OTC drugs were involved in 11% of all drug interactions. Drug interactions with Cumarins, quinolones, anti-epileptics and hydrochlorothiazide were seen frequently. Interactions that potentially cause QT prolongation, gastroduodenal toxicity and CNS depression were also common. Duplicate prescriptions were not found. Conclusion: Potential drug interactions are common in (hemato)oncology. Screening for drug interactions should take place routinely before administering cytotoxic drugs.

Original languageDutch
Pages (from-to)99-103
Number of pages5
JournalPharmaceutisch Weekblad
Issue number24
Publication statusPublished - 18 Jun 2010

Cite this

Van Leeuwen, R. W. F., Swart, E. L., Boom, F. A., Schuirenmaker, M. G., & Hugtenburg, J. S. (2010). Interacties en dubbelmedicatie bij poliklinische patiënten met kanker. Pharmaceutisch Weekblad, 145(24), 99-103.